Infinity Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Infinity Discovery, Inc.

Tao Liu

Alfredo C Castro

Catherine Anne Evans

Daniel A Snyder

Martin R Tremblay

Andre Lescarbeau

Michael J Grogan

Somarajannair Janardanannair

Thomas T Tibbitts

Louis Grenier

Yi Liu

Pingda Ren

Liansheng Li

Katrina Chan

Mark L Behnke

Zhihua Sui

Giovanni Cianchetta

Dawei Cui

Anil Kumar Padyana

Jingjing Ji

Stephane Peluso

Zhenwei Cai

Julian Adams

Edward Holson

Brian T Hopkins

Nii O Koney

Kristopher M Depew

David A Mann

Yves Leblanc

Lawrence Blas Perez

Gregg F Keaney

Marta Nevalainen

Lawrence K Chan

Lin-Chen Yu

Charles W Johannes

David Guenther Winkler

Brian C Austad

Vito J Palombella

Jeffery L Kutok

Theodore A Martinot

Charles Kung

Dennis John Underwood

Asimina T Georges Evangelinos

Michael Andrew Foley

Wei Deng

Christian C Fritz

Linping Zhang

Priscilla L White

Lisa A Marcaurelle

Ching Kam Lo

Nafeeza Hafeez

Andrew A Wylie

Dennis J Underwood

Michael A Foley

Edward B Holson

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Heterocyclic compounds and uses thereof

Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R, R, R, R, R, R, and Q are as defined herein.

Pyruvate kinase activators for use in treating blood disorders

Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R, R, L, and Lare as defined herein.

Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R, R, L, and Lare as defined herein.

Pyruvate kinase modulators and use thereof

Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R, R, R, R, R, R, and Q are as defined herein. 

Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R, R, L, and Lare as defined herein. 

Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): wherein R, R, L, and Lare as defined herein. 

Provided herein are compounds of Formula (I&#x2033;) or (A&#x2033;), pharmaceutical compositions comprising the compounds, and methods of use thereof. The compounds provided herein modulate kinase activity, including PI3 kinase activity, and are useful for treating diseases and conditions associated with kinase activity, including PI3 kinase activity. 

The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same.

Methods of treating a fatty acid amide hydrolase-mediated condition

Growing community of inventors

Ashland, MA, United States of America

Tao Liu